Given the high occurrence of this mutation and the selectivity of Jak2 inhibitors for EGFRvIII-positive glioma cells, stratifying patients by EGFR mutation status may be an important factor in assigning Jak2 inhibitor therapy. The gene discussed is EGFR; the disease is central nervous system cancer.